November 29, 2021

Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3Kα and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability

— Rapid discovery of lead compounds driven by Scorpion’s Precision Oncology 2.0 strategy, and enabled by its fully integrated drug-hunting platform — — Both mutant PI3Kα...

November 22, 2021

Scorpion Therapeutics Announces Appointment of Brian Piper as Chief Financial Officer

BOSTON, Mass. – November 22, 2021 – Scorpion Therapeutics, Inc. (“Scorpion”), a next-generation oncology company whose goal is to develop best- and first-in-class precision medicines for...

October 25, 2021

Scorpion Therapeutics Expands Executive Leadership Team with Three Key Appointments

– Kristin Schuhwerk joins as Chief Operating Officer –  – Andrew Fedder joins as General Counsel –  –  Adam Friedman, M.D., Ph.D. promoted to President, Corporate...


Endpoints (Subscription Required)   |   September 22, 2021

Scorpion Therapeutics was named as one of the 2021 Endpoints 11, a group of the most promising up-and-coming private biotechnology companies.  

STAT (Subscription Required)   |   July 9, 2021

Scorpion Therapeutics hired Axel Hoos as chief executive officer. Previously, he worked at GlaxoSmithKline, where he was senior vice president of R&D governance chair and therapeutic area...

Boston Business Journal   |   July 9, 2021

Just eight months out of stealth, precision medicine startup Scorpion Therapeutics has netted a big fish in Axel Hoos, the head of oncology at GlaxoSmithKline plc,...

Scrip (Subscription Required)   |   July 7, 2021

Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10...

BioCentury (Subscription Required)   |   July 7, 2021

GSK is losing one of the principal architects of its oncology renaissance as immuno-oncology pioneer Axel Hoos prepares to leave the company for his first CEO...

Fierce Biotech   |   July 7, 2021

After leading oncology teams at GlaxoSmithKline and Bristol Myers Squibb, Axel Hoos, M.D., Ph.D., is heading back to biotech.  

Endpoints   |   July 7, 2021

Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and...

Fierce Biotech   |   January 12, 2021

Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.

Boston Globe   |   January 12, 2021

Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.

Endpoints News   |   January 12, 2021

Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A.
Media Contact

Ravi Moorthy
Scorpion Therapeutics

Investor Contact

Hanna Deresiewicz
Stern Investor Relations, Inc.